Share this article
Share this article
BOSTON, Feb. 17, 2021 /PRNewswire/ The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with GBS’s transistor technology in developing a multiplexed COVID-19 biomarker diagnostic. Credit: Wyss Institute at Harvard University
Share this article
Share this article
LOS ANGELES, Feb. 17, 2021 /PRNewswire/ As the war against COVID-19 rages on, EZ STAK and Wellness Systems, Inc. today announced the launch of what is believed to be the pandemic s first mobile testing and vaccination station. Designed for rapid and secure deployment, the U.S.-built Charlie Station can also be modified for non-COVID uses and is eligible for FEMA funding.
Charlie Station, a mobile testing and vaccination station
EZ STAK and Wellness Systems Inc partnered together to offer a mobile-ready station that allows companies to safely conduct COVID-19 screening and testing, distribute personal protective equipment, and provide COVID-19 vaccination.
Share this article
Share this article
LONDON, Feb. 17, 2021 /PRNewswire/ LYPHE Group, U.K. s leading medical cannabis provider, with more than 60% of the British patient market, and Canadian independent EU GMP manufacturer, Northern Green have entered into a supply partnership that will see a range of indoor grown flowers enter the market under the brand name of NOIDECS.
The flowers are now available in the private market and through NOIDECS inclusion on the formulary of Europe s largest patient real world data registry, Drug Science s Project Twenty21. Under the agreement, NOIDECS is also expanding the range into other International territories.
/PRNewswire/ Everlywell, a leading digital health company, today announced that the Everlywell COVID-19 Test Home Collection Kit DTC is now available for.
University Hospitals Is First in Cleveland To Offer GT Medical Technologies New Targeted Therapy for Brain Tumors
GammaTile® Therapy Is Shown To Slow Brain Tumor Progression, Designed To Improve Patient and Caregiver Quality of Life
News provided by
Share this article
Share this article
CLEVELAND, Feb. 17, 2021 /PRNewswire/ A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile
® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman Cancer Center is the first to offer this to patients with brain tumors in Cleveland.